Hosted on MSN14d
Non-Opioid Pain Medication Journavx Gets FDA Approval
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for adults experiencing moderate to severe acute pain ... also allowed to take ...
Healio15d
FDA approves nonopioid Journavx for moderate to severe acute pain
Perspective from Anita Gupta, DO, PharmD, MPP, GMP, FASA The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a press release.
Kaleido Scope12y
What is expected in recovering from a traumatic brain injury?
The prognosis for mild TBI is usually better than for a moderate TBI, and the prognosis for moderate TBI is usually better than for a severe TBI. With a concussion (mild TBI), most people recover most ...
GlobalData on MSN3mon
FDA grants breakthrough status to J&J’s nipocalimab for SjD treatment
The US Food and Drug Administration (FDA) has awarded the second breakthrough therapy designation (BTD) to Johnson & ...
Pharmabiz1mon
CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis
This topical JAK inhibitor ointment, developed using CAGE Bio’s proprietary ionic liquid technology, represents a potential breakthrough for low body surface area (BSA), moderate to severe atopic ...